Unknown

Dataset Information

0

Anti-CD20 monoclonal antibodies: historical and future perspectives.


ABSTRACT: Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

SUBMITTER: Lim SH 

PROVIDER: S-EPMC2805725 | biostudies-other | 2010 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim Sean H SH   Beers Stephen A SA   French Ruth R RR   Johnson Peter W M PW   Glennie Martin J MJ   Cragg Mark S MS  

Haematologica 20090922 1


Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. ...[more]

Similar Datasets

| S-EPMC6343614 | biostudies-literature
| S-EPMC5688039 | biostudies-literature
| S-EPMC2779347 | biostudies-other
| S-EPMC8356891 | biostudies-literature
| S-EPMC4622538 | biostudies-literature
| S-EPMC6485963 | biostudies-literature
| S-EPMC8873567 | biostudies-literature
| S-EPMC7128139 | biostudies-literature
| S-EPMC8707981 | biostudies-literature
| S-EPMC6826541 | biostudies-literature